FindTrial
Sign In

A medical records based multicenter real-world study of neoadjuvant therapy for early HER2-positive breast cancer in China (CSBrS-015)

Efficacy and safety of trastuzumab and patuzumab combined with neoadjuvant chemotherapy in the treatment of early HER2 positive breast cancer: a national multicenter real world study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100046929
Enrollment
Unknown
Registered
2021-05-31
Start date
2021-05-31
Completion date
Unknown
Last updated
2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Trastuzumab + Pertuzumab dual target therapy group :Nil
Trastuzuma single target therapy group :Nil

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Core needle biopsy is diagnosed as HER2-positive female breast cancer; 2. Meet the indications of neoadjuvant therapy; 3. Accept the neoadjuvant treatment plan of trastuzumab combined with chemotherapy or trastuzumab + Pertuzumab combined with chemotherapy recommended by NCCN breast cancer clinical practice guidelines or CSCO breast cancer diagnosis and treatment guidelines; 4. Accept neoadjuvant therapy >= 4 cycles and accept established surgical treatment; 5. Complete clinical pathological data.

Exclusion criteria

Exclusion criteria: There are distant metastases.

Design outcomes

Primary

MeasureTime frame
Pathological Complete Response;—

Countries

China

Contacts

Public ContactLiu Yinhua

Peking University First Hospital

liuyinhua7520@163.com+86 10 83572654

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026